Entries |
Document | Title | Date |
20080221207 | USE OF SPECIFIC CYKLOLIGNANS - The invention refers to the use of specific cyclolignans, wherein the carbon atoms in positions 9 and 9′ have cis configuration, for inhibition of the insulin-like growth factor-1 receptor. Said compounds can be used for treatment of IGF-1R dependent diseases, such as cancer, psoriasis, atherosclerosis and acromegaly. A preferred compound is picropodophyllin. | 09-11-2008 |
20080269321 | Therapeutic Combinations for the Treatment or Prevention of Depression - Therapeutic combinations useful in the treatment or prevention of depression or other mood disorders, to pharmaceutical compositions containing said combinations, and to their use in the treatment or prophylaxis of depression or other mood disorders are provided. Such compounds are of formula I: | 10-30-2008 |
20080280975 | Methods of preventing the serotonin syndrome and compositions for use thereof - The present invention is directed at methods for preventing or minimizing the intensity of the serotonin syndrome in humans and lower animals which comprises administering proserotonergic agents and serotonin surge protectors. The present invention is also directed to pharmaceutical compositions comprising proserotonergic agents and serotonin surge protectors useful for carrying out the method of the present invention. | 11-13-2008 |
20080287530 | Tripolide Lactone Ring Derivatives as Immunomodulators and Anticancer Agents - Disclosed are compounds based on lactone ring modifications of triptolide and hydroxylated triptolide, for use in therapy, such as antiproliferative, anticancer, and immunosuppressive therapy. | 11-20-2008 |
20080287531 | Preventive and/or Therapeutic Agent for Sleeping Disorder - The present invention provides a preventive and/or therapeutic agent for sleeping disorder, which comprises, as an active ingredient, a dibenzo[b,e]oxepine derivative represented by formula (I): | 11-20-2008 |
20080306145 | Preparation Of Ginkgolide And F-Seco-Ginkgolide Lactols - The present invention relates to synthesis of C | 12-11-2008 |
20090036521 | Process for Production of Optically Active Amine Derivatives - An industrial process for production of high-purity optically active amine derivatives in high yield while inhibiting the formation of by-products, which comprises subjecting (E)-2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-ylidene)ethylamine to asymmetric reduction, catalytically reducing the obtained product at a reaction temperature of 40 to 100° C. and a pH of 3 to 9, subjecting the obtained (S)-2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethylamine to propionylation, and then crystallizing the reaction mixture. | 02-05-2009 |
20090036522 | Tablet Containing Hardly Soluble Active Ingredient - A tablet showing regulated variation in dissolution from lot to lot which contains from about 3 to about 50% by weight (w/w), based on the whole tablet, of (S)—N—[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide, magnesium stearate and hydroxypropylcellulose having a viscosity of about 1 to about 4 mPa·s. | 02-05-2009 |
20090042977 | Anticancer Compound, Intermediate Therefor, and Processes for Producing These - The present invention provides a method for easily and inexpensively preparing a racemate or an optically-active 2-(1-hydroxyethyl)-5-hydroxynaphtho[2,3-b]furan-4,9-dione in high yields, 2-acetyl-2,3-dihydro-5-hydroxynaphtho[2,3-b]furan-4,9-dione which is useful as an intermediate for preparing NFD, and an anticancer agent comprising 2-(1-hydroxyethyl)-5-hydroxynaphtho[2,3-b]furan-4,9-dione as an active ingredient. | 02-12-2009 |
20090076135 | DEUTERIUM-ENRICHED HYDROMORPHONE - The present application describes deuterium-enriched hydromorphone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-19-2009 |
20090076136 | THERAPEUTIC AGENT - The present invention relates to a therapeutic agent or prophylactic agent for a disease accompanying an abnormality in an amount of insulin or insulin response, an insulin-mimetic action agent, a food, beverage, or feed, an agent for enhancement of glucose uptake into a cell, and an agent for inducing differentiation into an adipocyte, each comprising as an effective ingredient at least one compound selected from the group consisting of specified compounds having an insulin-mimetic action, derivatives thereof, and pharmacologically acceptable salts thereof. | 03-19-2009 |
20090082432 | DEUTERIUM-ENRICHED RAMELTEON - The present application describes deuterium-enriched ramelteon, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-26-2009 |
20090082433 | PREVENTATIVE TREATMENT AND REMISSION OF ALLERGIC DISEASES - The invention provides the use of at least one plant selected from plants of the family Zingiberaceae in the preparation of a medicament for use in the treatment or prophylaxis of allergic diseases. The plant is optionally selected from the genera | 03-26-2009 |
20090093539 | ANTI-ANGIOGENIC COMPOSITIONS AND METHODS OF USE THEREOF - The present invention provides methods of reducing angiogenesis in an individual. The methods generally involve administering to the individual an effective amount of a tanshinone compound. The methods are useful to treat conditions associated with or resulting from angiogenesis, particularly pathological angiogenesis. The invention further provides methods of treating a condition associated with or resulting from angiogenesis. | 04-09-2009 |
20090105332 | PROCESSES OF MAKING SESQUITERPENOID TASHIRONIN, ITS ANALOGS AND THEIR USES - A compound having the structure of the formula (genus of compound 1 excluding Tashironin or Debenzoyltashironin) | 04-23-2009 |
20090143463 | Therapeutic Agent and Treatment Method for Ameliorating Uremia - A therapeutic agent and a treatment method for uremia of human and animals, which therapeutic agent can be easily taken, has lower side effects, and which is not expensive in view of medical economics, are disclosed. The therapeutic agent for uremia in patients suffering from chronic renal failure comprises as an effective ingredient a prostaglandin I | 06-04-2009 |
20090163584 | THERAPEUTIC AGENT FOR RENAL FAILURE - A therapeutic agent for renal failure including, as an active ingredient, a 4,8-inter-m-phenylene prostaglandin I | 06-25-2009 |
20090264521 | Percutaneous absorption preparation - Percutaneous absorption preparations which make it possible to absorb compounds having a melatonin receptor agonist activity via a convenient administration system, have favorable blood-drug-concentration-time profile and can exert a therapeutic effect on a disease caused by a decrease in secretion of melatonin at night. | 10-22-2009 |
20090281176 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES - A process for the preparation of ramelteon and intermediates useful in the process. The process suitable for industrial scale provides increased yield and/or greater purity with fewer process steps. | 11-12-2009 |
20090306200 | Prophylactic or Therapeutic Agent for Nocturnal Conduct Disorder Associated With Dementia - The present invention provides a prophylactic or therapeutic agent for nocturnal conduct disorders associated with dementia, comprising (S)—N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide. | 12-10-2009 |
20090312413 | Composition Comprising Tanshinone Compounds Isolated From The Extract Of Salviae Miltiorrhizae Radix For Treating Or Preventing Cognitive Dysfunction And The Use Thereof - A composition comprising tanshinone compounds selected from the group consisting of miltirone, 1,2-didehydromiltirone, tanshinone IIA, tanshinone I and dihydrotanshinone I isolated from | 12-17-2009 |
20100004327 | Novel Use of Ansamycin Antibiotics And Method of Screening Novel Angiogenesis Inhibitor - The present invention provides novel angiogenesis inhibitors effective, safe and highly practical for inhibition of angiogenesis in various diseases, and a method for screening the same. The active ingredients of the angiogenesis inhibitors of the present invention comprise ansamycin antibiotics such as rifampicin, rifamycin SV and 3-formyl rifamycin, which have long been used extensively as antibacterial agents for treating tuberculosis or Gram-positive bacterial infections. The active ingredients of the present invention have excellent angiogenesis-inhibiting activity. The angiogenesis inhibitor of the present invention is effective for inhibition of angiogenesis in malignant tumors, diabetic retinopathy, retinal angiogenesis, inflammatory diseases, and angiogenesis accompanying cardiovascular remodeling, etc., and can be used as therapeutic agents against each disease, etc. Further, the screening method of the present invention makes it possible to perform an effective screening of angiogenesis-inhibiting substances by detecting angiogenesis-inhibiting signals based on gene expression levels. | 01-07-2010 |
20100029760 | Obesity and Metabolic Syndrome Treatment with Tanshinone Derivatives Which Increase Metabolic Activity - The present invention relates to a composition for preventing and treating metabolic syndrome, containing tanshinone derivatives as an effective ingredient. More specifically, the present invention relates to a composition for preventing and treating metabolic syndrome, containing tanshinone derivatives that exhibit superior activity in enhancing metabolic activity, as an effective ingredient. | 02-04-2010 |
20100048692 | Naphthofuranone Derivatives as Specific Inhibitors of Thymidylate Synthases - Synthetic compounds of 1,2-naphthalein moelcules (I) having specific inhibitory properties of the enzymatic activity of thymidylate synthases of bacterial species, their preparation, their pharmaceutical composition and use in the treatment and prophylaxis of infectious pathologies are disclosed. | 02-25-2010 |
20100048693 | Treatment of COPD - The present invention provides methods for treating chronic obstructive pulmonary disease. In some embodiments of the invention, methods for treating COPD comprise administering PGI | 02-25-2010 |
20100056622 | Methods of Using Ramelteon to Treat Patients Suffering from a Variety of Neurodegenerative Diseases - Methods of using ramelteon to treat patients suffering from a variety of neurodegenerative diseases are disclosed. | 03-04-2010 |
20100168227 | Preventative Treatment and Remission of Allergic Diseases - The invention provides the use of at least one plant selected from plants of the family Zingiberaceae in the preparation of a medicament for use in the treatment or prophylaxis of allergic diseases. The plant is optionally selected from the genera | 07-01-2010 |
20100204315 | AGENTS FOR PREVENTING ATTACHMENT OF BARNACLE CONSISTING OF ORGANIC SOLVENT EXTRACTS OF RED ALGA LAURENCIA SP. AND COMPOUNDS ISOLATED THEREFROM - An object of the present invention is to provide organic solvent extracts of red algae | 08-12-2010 |
20100222425 | COMPOSITIONS AND TREATMENT METHODS-2 - The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3β-yl)-β-D-glucopyranosiduronate, 16α,3α-dihydroxy-5α-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene, 3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method. | 09-02-2010 |
20100267821 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME - The present invention provides a prophylactic or therapeutic agent for irritable bowel syndrome, which comprises a compound represented by formula (I): | 10-21-2010 |
20100286259 | EPOXY-GUAIANE DERIVATIVES AND TREATMENT OF CANCER - Disclosed are englerins and derivatives (I) thereof useful in the treatment of a number of cancers, particularly renal cancer, as well as pharmaceutical compositions and method of treating a patient with the use of these derivatives. The englerins, for example Englerin A and Englerin B, can be isolated from the plant | 11-11-2010 |
20100292318 | ANTIBACTERIAL COMPOSITION COMPRISING SALVIA EXTRACTS - The present invention relates to a selectively purified tanshinone compounds containing extract from the root of a | 11-18-2010 |
20100331402 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR ATTENTION DEFICIT/HYPERACTIVITY DISORDER - The present invention provides a novel prophylactic or therapeutic agent for attention deficit/hyperactivity disorder. | 12-30-2010 |
20110065786 | SYNTHESIS OF ROCAGLAMIDE NATURAL PRODUCTS VIA PHOTOCHEMICAL GENERATION OF OXIDOPYRYLIUM SPECIES - The present invention provides new strategies for the synthesis of compounds of the rocaglamide family and related natural products. In particular, the new biomimetic synthetic approach involves photochemical generation of an oxidopyrylium species from a 3-hydroxychromone derivative followed by 1,3-dipolar cycloaddition of the oxidopyrylium species to a dipolarophile. This approach can be used for the formation of adducts containing an aglain core structure. Methods for the conversion of aglain core structures to aglain, rocaglamide and forbaglin ring systems are also provided. The present invention also relates to the use of rocaglamide/aglain/forbaglin derivatives for the manufacture of medicaments for use in the treatment of cancer or cancerous conditions, disorders associated with cellular hyperproliferation, or NF-κB-dependent conditions. | 03-17-2011 |
20110098351 | Lactone compounds which can be used as antioxidant agents in pharmaceutical, cosmetic or food compositions and their method of preparation - The subject of the present invention is specific lactone compounds which can be used as antioxidant agents in pharmaceutical or cosmetic compositions or in food products, the said compounds containing a naphthalene ring onto which two lactone units are grafte. | 04-28-2011 |
20110130452 | STORE-OPERATED CALCIUM CELLULAR ASSAY - The present technology provides a cell based assay for identifying compounds that modulate store-operated ionic calcium levels using itpr mutant cell lines, such as itpr-ku cells, which have abnormal ionic calcium levels. | 06-02-2011 |
20110184058 | SYNTHESIS OF 6,7-DIHYDRO-1H-INDENO[5, 4-B] FURAN-8(2H)-ONE AS INTERMEDIATE IN THE PREPARATION OF REMELTEON - The present invention describes the preparation of 6,7-dihydro-1H-indeno[5,4-b]furan-8(2H)-one, a key intermediate in preparation of ramelteon. The present invention also describes further preceding intermediate compounds useful for the synthesis of 6,7-dihydro-1H-indeno[5,4-b]furan-8(2H)-one. | 07-28-2011 |
20110224293 | USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICAMENT FOR USE IN THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATION OR OF MORTALITY - Methods of using dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality, articles of manufacture and packages related thereto. | 09-15-2011 |
20110263700 | ANTROCIN CONTAINING PHARMACEUTICAL COMPOSITIONS FOR INHIBITING CANCER CELLS - This subject invention is directed to a pharmaceutical composition for the inhibition of cancer cells, comprising an effective amount of a compound of formula I (Sesquiterpene lactones, antrocin) or pharmaceutically acceptable salts thereof, together with a pharmaceutically acceptable carrier. | 10-27-2011 |
20110319485 | Composition Having Anti-Helicobacter Pylori Activity And Its Application To Inhibit Helicobacter Pylori - The present invention provides a composition having anti- | 12-29-2011 |
20120022153 | TRICYCLIC CONDENSED HETEROCYCLIC COMPOUND, PROCESS OF PRODUCING SAME, AND USE THEREOF - A novel compound derived from the culture product of an actinomycete and having an antitumor activity is provided. Provided is a compound represented by any one of formulas (I), (II) and (III) | 01-26-2012 |
20120083526 | SYNTHESIS OF 1-(2,3-DIHYDROBENZOFURAN-4-YL)ETHANONE AS INTERMEDIATE IN THE PREPARATION OF RAMELTEON - The present invention relates in general to the field of organic chemistry and in particular to the preparation of 1-(2,3-dihydrobenzofuran-4-yl)ethanone, an intermediate in preparation of (S)—N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide, i.e. ramelteon. | 04-05-2012 |
20120083527 | Anticancer Agents - The present disclosure relates generally to compositions and methods for treating cancer. In some aspects, novel spirohexenolides and methods of using and producing them are described. | 04-05-2012 |
20120088825 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS - Disclosed herein are compounds of Formula I | 04-12-2012 |
20120088826 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE AMINE DERIVATIVES - An industrial process for production of high-purity optically active amine derivatives in high yield while inhibiting the formation of by-products, which comprises subjecting (E)-2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-ylidene)ethylamine to asymmetric reduction, catalytically reducing the obtained product at a reaction temperature of 40 to 100° C. and a pH of 3 to 9, subjecting the obtained (S)-2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethylamine to propionylation, and then crystallizing the reaction mixture. | 04-12-2012 |
20120101153 | ROCAGLAOL DERIVATIVES AS CARDIOPROTECTANT AGENTS AND AS ANTINEOPLASTIC AGENTS - The present invention discloses new rocaglaol derivatives and the use of rocaglaol derivatives to prevent or to limit the cardiotoxicity of an antineoplastic agent, in particular to prevent or to limit the apoptosis of cardiomyocytes induced by such agent. | 04-26-2012 |
20120225936 | METHOD FOR PRODUCING TRIPTOLIDE - The invention relates to a method for producing triptolide from a suspension cell culture of | 09-06-2012 |
20120259005 | BRCA1-Based Breast or Ovarian Cancer Prevention Agents and Methods of Use - A pharmaceutical composition for use in treating, inhibiting, and/or preventing breast and/or ovarian cancer can include: a molecule having a structure of one of Compounds 1-38, pharmaceutically acceptable salt thereof, or analog thereof; and a pharmaceutically acceptable carrier containing the compound. The pharmaceutically acceptable carrier can be configured for oral, systemic, transdermal, intranasal, suppository, parenteral, intramuscular, intravenous, or subcutaneous administration. The compound can be present in the composition in a therapeutically effective amount for treating, inhibiting, and/or preventing breast and/or ovarian cancer. Also, the compound can be present in a therapeutically effective amount for enhancing production of BRCA1. | 10-11-2012 |
20120270935 | FORMULATIONS - An antimicrobial and/or anti-acne formulation containing either usnic acid or an usnate, together with (a) a primary solvent or solvent system in which the usnic acid or usnate is at least partially dissolved; (b) a glycol; and (c) a hydrophobic fatty acid, fatty alcohol or derivative thereof. The formulation may also contain (d) an alkylene glycol derivative. | 10-25-2012 |
20120277304 | SODIUM TRANSHINONE IIA SULFONATE HYDRATE AND PREPARATION METHOD AND USE THEREOF - The present invention relates to sodium tanshinone IIA sulfonate hydrates as well as preparation methods and uses thereof. The sodium tanshinone IIA sulfonate hydrates have molecular formula of C | 11-01-2012 |
20120309823 | PERCUTANEOUS ABSORPTION PREPARATIONS - Percutaneous absorption preparations which make it possible to absorb compounds having a melatonin receptor agonist activity via a convenient administration system, have favorable blood-drug-concentration-time profile and can exert a therapeutic effect on a disease caused by a decrease in secretion of melatonin at night. | 12-06-2012 |
20130023586 | USE OF TRICYCLIC SESQUITERPENE LACTONES IN THE TREATMENT OF OBESITY AND RELATED DISEASES AND NON-THERAPEUTIC TREATABLE CONDITIONS - A compound of the formula I, wherein the symbols are as defined in the remaining specification, or a mixture of two or more compounds of the formula I, for use as active ingredient in the therapeutic—including prophylactic—treatment of a warm-blooded animal for the regulation of body weight (preferred) and/or fat loss (preferred) and/or for the management of obesity and/or for improving the total cholesterol HDL/LDL ratio; where the compound(s) of the formula I may be present in free form, in the form of a pharmaceutically and/or nutraceutically acceptable salt, in the form of tautomers, in the form of esters and/or in the form of solvates, as well as related invention embodiments. | 01-24-2013 |
20130035384 | ORALLY DISPERSIBLE TABLET - The present invention provides a preparation with improved disintegration property, a preparation showing improved bioavailability of a medicament, production methods thereof and the like. A rapidly disintegrating preparation comprising granules comprising a medicament coated with a coating layer containing sugar or sugar alcohol; and a disintegrant. A production method of a rapidly disintegrating preparation including a step of producing granules comprising a medicament, a step of forming a coating layer containing sugar or sugar alcohol on the obtained granules and a step of mixing the coated granules with a disintegrant and molding the mixture. | 02-07-2013 |
20130035385 | ORALLY DISPERSIBLE TABLET - The present invention provides a preparation with improved disintegration property, a preparation showing improved bioavailability of a medicament, production methods thereof and the like. A rapidly disintegrating preparation comprising granules comprising a medicament coated with a coating layer containing sugar or sugar alcohol; and a disintegrant. A production method of a rapidly disintegrating preparation including a step of producing granules comprising a medicament, a step of forming a coating layer containing sugar or sugar alcohol on the obtained granules and a step of mixing the coated granules with a disintegrant and molding the mixture. | 02-07-2013 |
20130079397 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE AMINE DERIVATIVES - An industrial process for production of high-purity optically active amine derivatives in high yield while inhibiting the formation of by-products, which comprises subjecting (E)-2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-ylidene)ethylamine to asymmetric reduction, catalytically reducing the obtained product at a reaction temperature of 40 to 100° C. and a pH of 3 to 9, subjecting the obtained (S)-2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethylamine to propionylation, and then crystallizing the reaction mixture. | 03-28-2013 |
20130109749 | MICHELIOLIDE DERIVATIVES, MEDICINAL COMPOSITION, PRODUCING METHOD AND USAGE THEREOF | 05-02-2013 |
20130123352 | XANTHANODIEN FOR THE TREATMENT OF CANCER - The present invention relates to a method for the treatment or prophylaxis of a disease associated with hyperproliferative cellular division, comprising administering to a subject in need thereof a therapeutically effective dosage of the pharmaceutical composition comprising xanthanodien, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. | 05-16-2013 |
20130150437 | NAPHTHOQUINONES FOR DISEASE THERAPIES - The present invention discloses novel naphtho[2,3-b]furan-4,9-diones and naphtho[2,3-b]thiophene-4,9-diones and methods of making and using the same. The present invention also discloses pharmaceutical compositions comprising novel naphtho[2,3-b]furan-4,9-dione or naphtho[2,3-b]thiophene-4,9-diones for the treatment of various indications including proliferative diseases. | 06-13-2013 |
20130197075 | Method of treating acquired perforating dermatosis with cantharidin - A method of treating acquired perforating dermatosis. The method has the step of applying an amount of cantharidin to an area of skin in need of treatment thereof. | 08-01-2013 |
20130253049 | TREATMENT FOR PULMONARY HYPERTENSION - One embodiment relates to a method of treating pulmonary hypertension based upon co-administering to a subject in need thereof a pharmaceutically effective amount of an oral therapeutic agent for treating pulmonary hypertension and a pharmaceutically effective amount of an inhaled therapeutic agent for treating pulmonary hypertension. The benefit of the co-administration of these agents is to eliminate or reduce one or more side effects associated with mono-therapy of either agent, as well as one or more side effects associated with other administration routes such as subcutaneous or intravenous administration. | 09-26-2013 |
20130261176 | Method of Detecting Mechanosensing Responses in Bone Cells - This invention relates to a method of detecting mechanosensing responses in bone. More specifically, the present invention provides a method to detect the expression levels of genes in mechanosensing complex to predict impaired mechanosensing response. Further, the present invention disclosed a therapeutic method for preventing bone loss and defective in bone formation by modulating the activity of the mechanosensing complex. | 10-03-2013 |
20130289105 | HEPSIN INHIBITORS - Compositions and methods are provided for preventing or attenuating cancer progression or blocking metastasis in prostate cancer and other cancers (e.g., ovarian carcinoma, endometrial cancer, renal cell carcinoma) that are characterized by overexpression of the type II cell surface serine protease hepsin, based on the discovery of multiple disclosed compounds having activity as specific hepsin inhibitors. | 10-31-2013 |
20130310451 | TRICYCLIC LACTONES FOR TREATMENT OF CANCER - The present invention discloses novel compounds useful for the inhibition of IL-6/STAT signaling and/or PI3K/NF-κB signaling in the treatment of associated diseases or conditions, e.g. cancer. A pharmaceutical composition comprising such novel compounds, its use and a method thereof, is also disclosed. | 11-21-2013 |
20140057976 | USNIC ACID TOPICAL FORMULATION - Topical skin treatment formulation containing usnic acid or an usnate salt, dissolved in a solvent system comprising (i) dimethyl isosorbide; (ii) a C1 to C9 alkyl salicylate; and (iii) a glyceryl fatty acid ester. The solvent system may also comprise an alcohol, a polyoxyalkylene-based solvent, and/or a C1 to C4 alkyl glucose ester. The formulation may be used in the treatment of microbial conditions, in particular acne. The solvent system assists in the effective dissolution of the usnic acid or usnate and in targeting its delivery to relevant sites on the skin. | 02-27-2014 |
20140066499 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE AMINE DERIVATIVES - An industrial process for production of high-purity optically active amine derivatives in high yield while inhibiting the formation of by-products, which comprises subjecting (E)-2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-ylidene)ethylamine to asymmetric reduction, catalytically reducing the obtained product at a reaction temperature of 40 to 100° C. and a pH of 3 to 9, subjecting the obtained (S)-2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethylamine to propionylation, and then crystallizing the reaction mixture. | 03-06-2014 |
20140088188 | C13-HYDROXY DERIVATIVES OF OLEANOLIC ACID AND METHODS OF USE THEREOF - Disclosed herein are novel C13-hydroxy derivatives of oleanolic acid, including those of the formula: | 03-27-2014 |
20140235709 | ORALLY DISPERSIBLE TABLET - The present invention provides a preparation with improved disintegration property, a preparation showing improved bioavailability of a medicament, production methods thereof and the like. A rapidly disintegrating preparation comprising granules comprising a medicament coated with a coating layer containing sugar or sugar alcohol; and a disintegrant. A production method of a rapidly disintegrating preparation including a step of producing granules comprising a medicament, a step of forming a coating layer containing sugar or sugar alcohol on the obtained granules and a step of mixing the coated granules with a disintegrant and molding the mixture. | 08-21-2014 |
20140275237 | BERAPROST ISOMER AS AN AGENT FOR THE TREATMENT OF VIRAL INFECTION - In various embodiments the use of single isomer of beraprost as a therapeutic for the treatment of viral disease and other pathologies associated with the induction of a cytokine storm, such as influenza A viruses and the SARS-causing coronvirus and mutations thereof is provided. | 09-18-2014 |
20140323563 | USE OF STRIGOLACTONES AND STRIGOLACTONE ANALOGS FOR TREATING PROLIFERATIVE CONDITIONS - Compound of formula X wherein P | 10-30-2014 |
20140336249 | 2-ALKYL-OR-ARYL-SUBSTITUTED TANSHINONE DERIVATIVES, AND PREPARATION METHOD AND APPLICATION THEREOF - The present invention belongs to the field of natural medicine and pharmaceutical chemistry, and specifically relates to novel 2-alkyl- or 2-aromatic-substituted tanshinone I derivatives of formula (I) or a pharmaceutically acceptable salt thereof, to a process for the preparation of these compounds, compositions containing such compounds and their use in preparing antineoplastic medicaments. When Z═R, said derivative is 2-alkyl-substituted tanshinone I; when Z═Ar, said derivative is 2-aryl-substituted tanshinone I; when Z=Het, said derivative is 2-heteroaryl- or 2-heterocyclyl-substituted tanshinone I. | 11-13-2014 |
20140350096 | METHOD FOR CHEMICAL SYNTHESIS OF ANTROCIN AND USE THEREOF FOR SUPPRESSING NON-SMALL CELL LUNG CANCER - The present invention provides a method for preparing antrocin of pharmaceutically acceptable salts thereof via a series of gold-catalyzed cyclization to construct the (6-6-5) tricyclic core frame. The present invention also provides a use of a composition in preparing drugs for suppressing growth of non-small cell lung cancer cells, wherein the composition comprises an effective amount of antrocin or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier. | 11-27-2014 |
20150051277 | Compounds from Anisomeles Heyneana - The present invention describes use of compounds of formula 1 or 2 or their compositions for the treatment of leukemia and use of compound of formula 1 or its composition for treatment of infections caused due to | 02-19-2015 |
20150105457 | LINE LEAF INULA FLOWER LACTONE A AND METHODS FOR PREPARING AND USING THE SAME FOR TREATING MYOCARDITIS - Preparation and application of line leaf inula flower lactone A for treating myocarditis having a structure of | 04-16-2015 |
20150105458 | LINE LEAF INULA FLOWER LACTONE A AND METHODS FOR PREPARING AND USING THE SAME FOR TREATING MULTIPLE SCLEROSIS - Preparation and application of line leaf | 04-16-2015 |
20150344492 | MACROCYCLIC BENZOFURAN AND AZABENZOFURAN COMPOUNDS FOR THE TREATMENT OF HEPATITIS C - Compounds of formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. | 12-03-2015 |
20160022625 | TASHINONES AND THEIR DERIVATIVES: NOVEL EXCELLENT DRUGS FOR ALZHEIMER DISEASE - A method for disaggregating amyloid peptide aggregates the method comprising administering a tanshinone or a tanshinone derivatives to an amyloid peptide aggregate. The method may be useful for disaggregating amyloid peptide aggregates in a patient in need of such treatment, such as patients with Alzheimer's disease. | 01-28-2016 |
20160030384 | 2-ACETYLNAPHTHO[2,3-B]FURAN -4,9-DIONE FOR USE ON TREATING CANCER - The invention provides naphthofuran compounds, polymorphs of naphthofuran compounds, naphthofuran compounds in particle form, purified compositions that contain one or more naphthofuran compounds, purified compositions that contain one or more naphthofuran compounds in particle form, and methods of using these naphthofuran compounds, polymorphs, purified compositions and/or particle forms to treat subjects in need thereof. | 02-04-2016 |
20160038460 | COMPOSITIONS AND METHODS FOR DRUG-SENSITIZATION OR INHIBITION OF A CANCER CELL - The disclosure provides rifamycin and rifamycin derivative compositions, including rifabutin and rifabutin derivative compositions able to cause drug-sensitization in a cancer cell or inhibition of a cancer cell. The disclosure also provides methods of administering such compositions to cancer cells to sensitize them to drugs, such as chemotherapeutics, or directly inhibit them. The disclosure also provides methods of administering such compositions to increase reactive oxygen species (ROS), particularly superoxides, in cancer cells. The disclosure further provides methods of determining whether a cancer will respond to chemotherapeutics and whether to administer rifamycin or a rifamycin derivative based on ROS levels in cancer cells of a patient. | 02-11-2016 |
20160074357 | TETRAHYDROCANNABIVARIN FOR USE IN THE TREATMENT OF NAUSEA AND VOMITING - The present invention relates to the use of tetrahydrocannabivarin (THCV) in the treatment of nausea and vomiting. Preferably the THCV is isolated and/or purified from cannabis plant extracts. Preferably the nausea and/or vomiting is caused by the effects of a medication such as a chemotherapeutic agent. | 03-17-2016 |
20160143975 | METHOD FOR PRODUCING TRIPTOLIDE - The invention relates to a method for producing triptolide from a suspension cell culture of | 05-26-2016 |
20160193178 | BERAPROST-CONTAINING PATCH | 07-07-2016 |
20220133680 | Compositions of Azadirachta Indica and Methods of Treating Cancer - The disclosure relates to compositions and methods of treating cancer in a subject. The method comprises administering to a patient in need of treatment an effective amount of supercritical CO | 05-05-2022 |